ENTRADA THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ENTRADA THERAPEUTICS, INC. (TRDA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.15M, a 2.02% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.74M, a 6.74% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.12M, a 5.27% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.05M, a 9.22% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $19.61M, a 9.46% increase from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $17.91M, a 36.64% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $13.11M, a 32.50% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $9.89M, a 291.73% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.15M 10-Q · filed 2026-08-05 | $9.89M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $4.74M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $19.61M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $5.12M 10-Q · filed 2025-11-06 | $10.16M derived: sum of 2 quarters · filed 2026-08-05 | $15.25M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $5.05M 10-Q · filed 2026-08-05 | $10.13M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $5.09M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $17.91M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $4.86M 10-Q · filed 2025-11-06 | $9.48M derived: sum of 2 quarters · filed 2025-11-06 | $13.21M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $4.62M 10-Q · filed 2025-11-06 | $8.36M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $3.73M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $13.11M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $3.40M 10-Q · filed 2024-11-05 | $6.51M derived: sum of 2 quarters · filed 2024-11-05 | $9.27M derived: sum of 3 quarters · filed 2024-11-05 | |
| 2023-06-30 | $3.12M 10-Q · filed 2024-11-05 | $5.87M derived: sum of 2 quarters · filed 2024-11-05 | ||
| 2023-03-31 | $2.75M 10-Q · filed 2024-11-05 | |||
| 2022-12-31 | $9.89M 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $2.71M 10-Q · filed 2023-11-07 | $5.22M derived: sum of 2 quarters · filed 2023-11-07 | $7.01M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.51M 10-Q · filed 2023-11-07 | $4.31M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $1.79M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $2.53M 10-K · filed 2023-03-06 | |||
| 2021-09-30 | $577.00K 10-Q · filed 2022-11-07 | $903.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.07M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $326.00K 10-Q · filed 2022-11-07 | $490.00K derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $164.00K 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $325.00K 10-K · filed 2022-03-15 | |||
| 2020-09-30 | $75.00K 10-Q · filed 2021-12-09 | $149.00K derived: sum of 2 quarters · filed 2021-12-09 | $227.00K derived: sum of 3 quarters · filed 2021-12-09 | |
| 2020-06-30 | $74.00K 10-Q · filed 2021-12-09 | $152.00K derived: sum of 2 quarters · filed 2021-12-09 | ||
| 2020-03-31 | $78.00K 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |